PURPOSE: To describe respiratory symptoms and pulmonary function among long-term survivors of non-small cell lung cancer (NSCLC), and their relationship to quality of life (QOL). METHODS: Cross-sectional survey of disease-free, 5-year minimum survivors of NSCLC (n = 142; 54% women; average age, 71 years); the majority (74%) had received a lobectomy. Analysis included frequency of self-reported respiratory symptoms (cough, phlegm, wheezing, breathlessness) as measured by the American Thoracic Society questionnaire, pulmonary function findings from hand-held spirometry, and QOL (Short Form-36). RESULTS: Two thirds of survivors reported at least one respiratory symptom (mean, 1.3; SD, 1.2): 25% cough, 28% phlegm, 31% wheezing, and 39% dyspnea. Twenty-one percent reported that they spent most of the day in bed in the past 12 months because of respiratory symptoms. Average FEV(1) percentage predicted was 68% (SD, 23); 21% had < 50% predicted FEV(1). Based on spirometry results, 36% had a moderate/severe obstructive and/or restrictive ventilatory disorder. Survivors exposed to second-hand smoke (28%) were more than three times as likely to report respiratory symptoms. Respiratory symptom burden contributed to diminished QOL in several domains. CONCLUSIONS: The majority of these survivors experienced respiratory symptoms, and more than one third reported dyspnea, including one of five patients with seriously diminished pulmonary function. Symptom burden, rather than ventilatory impairment, contributed to diminished QOL. Further study is needed to determine the patterns and effective management of posttreatment respiratory symptoms on survivors of lung cancer.
PURPOSE: To describe respiratory symptoms and pulmonary function among long-term survivors of non-small cell lung cancer (NSCLC), and their relationship to quality of life (QOL). METHODS: Cross-sectional survey of disease-free, 5-year minimum survivors of NSCLC (n = 142; 54% women; average age, 71 years); the majority (74%) had received a lobectomy. Analysis included frequency of self-reported respiratory symptoms (cough, phlegm, wheezing, breathlessness) as measured by the American Thoracic Society questionnaire, pulmonary function findings from hand-held spirometry, and QOL (Short Form-36). RESULTS: Two thirds of survivors reported at least one respiratory symptom (mean, 1.3; SD, 1.2): 25% cough, 28% phlegm, 31% wheezing, and 39% dyspnea. Twenty-one percent reported that they spent most of the day in bed in the past 12 months because of respiratory symptoms. Average FEV(1) percentage predicted was 68% (SD, 23); 21% had < 50% predicted FEV(1). Based on spirometry results, 36% had a moderate/severe obstructive and/or restrictive ventilatory disorder. Survivors exposed to second-hand smoke (28%) were more than three times as likely to report respiratory symptoms. Respiratory symptom burden contributed to diminished QOL in several domains. CONCLUSIONS: The majority of these survivors experienced respiratory symptoms, and more than one third reported dyspnea, including one of five patients with seriously diminished pulmonary function. Symptom burden, rather than ventilatory impairment, contributed to diminished QOL. Further study is needed to determine the patterns and effective management of posttreatment respiratory symptoms on survivors of lung cancer.
Authors: Jinmyoung Cho; Peter Martin; Jennifer Margrett; Maurice MacDonald; Mary Ann Johnson; Leonard W Poon; S M Jazwinski; R C Green; M Gearing; J L Woodard; J S Tenover; I C Siegler; C Rott; W L Rodgers; D Hausman; J Arnold; A Davey Journal: Gerontology Date: 2011-11-15 Impact factor: 5.140
Authors: Matthew M Clark; Paul J Novotny; Christi A Patten; Sarah M Rausch; Yolanda I Garces; Aminah Jatoi; Jeff A Sloan; Ping Yang Journal: Lung Cancer Date: 2008-02-19 Impact factor: 5.705
Authors: Jarrod T Bullard; Jan M Eberth; Amanda K Arrington; Swann A Adams; Xi Cheng; Ramzi G Salloum Journal: South Med J Date: 2017-02 Impact factor: 0.954
Authors: Marc B Feinstein; Paul Krebs; Elliot J Coups; Bernard J Park; Richard M Steingart; Jack Burkhalter; Amy Logue; Jamie S Ostroff Journal: J Thorac Oncol Date: 2010-08 Impact factor: 15.609
Authors: Mary E Cooley; Ruth McCorkle; George J Knafl; Joan Rimar; Margaret J Barbieri; Marianne Davies; John Murren Journal: Qual Life Res Date: 2005-06 Impact factor: 4.147
Authors: Nalaka S Gooneratne; Grace E Dean; Ann E Rogers; J Emeka Nkwuo; James C Coyne; Larry R Kaiser Journal: Lung Cancer Date: 2007-08-31 Impact factor: 5.705
Authors: Giuseppe Cardillo; Lorenzo Spaggiari; Domenico Galetta; Francesco Carleo; Luigi Carbone; Aldo Morrone; Alberto Ricci; Francesco Facciolo; Massimo Martelli Journal: Interact Cardiovasc Thorac Surg Date: 2013-03-25
Authors: Anita R Peoples; Peter W Bushunow; Sheila N Garland; Charles E Heckler; Joseph A Roscoe; Luke L Peppone; Deborah J Dudgeon; Jeffrey J Kirshner; Tarit K Banerjee; Judith O Hopkins; Shaker R Dakhil; Marie A Flannery; Gary R Morrow Journal: Support Care Cancer Date: 2015-09-02 Impact factor: 3.603